Advertisement

Applied Microbiology and Biotechnology

, Volume 81, Issue 2, pp 311–317 | Cite as

High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli

  • Tingmei Ye
  • Zhihua LinEmail author
  • Huanzong Lei
Applied Genetics and Molecular Biotechnology

Abstract

Antibodies currently constitute the most rapidly growing class of human therapeutics; however, the high-yield production of recombinant antibodies and antibody fragments is a real challenge. High expression of active single-chain antibody fragment (scFv) in Escherichia coli has not been successful, as the protein contains three intramolecular disulfide bonds that are difficult to form correctly in the bacterial intracellular environment. To solve this problem, we fused the scFv gene against VEGF165 with a small ubiquitin-related modifier gene (SUMO) by synthesizing an artificial SUMO–scFv fusion gene that was highly expressed in the BL21(DE3) strain. The optimal expression level of the soluble fusion protein, SUMO–scFv, was up to 28.5% of the total cellular protein. The fusion protein was purified by Ni nitrilotriacetic acid (NTA) affinity chromatography and cleaved by a SUMO-specific protease to obtain the native scFv, which was further purified by Ni-NTA affinity chromatography. The result of the high-performance liquid chromatography showed that the purity of the recombinant cleaved scFv was greater than 98%. The primary structure of the purified scFv was confirmed by N-terminal amino acid sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy analysis. In vitro activity assay demonstrated that the recombinant scFv could dose-dependently inhibit VEGF165-induced human umbilical vein-derived endothelial cell proliferation. The expression strategy presented in this study allows convenient high yield and easy purification of recombinant scFv with native sequences.

Keywords

Vascular endothelial growth factor scFv Small ubiquitin-related modifier Purification 

Notes

Acknowledgments

This work was supported by grants from Scientific and Technological Program of Zhejiang Province (2006C33075; to Prof. Zhihua Lin).

References

  1. Byun J, Heard JM, Huh JE, Park SJ, Jung EA, Jeong JO, Gwon HC, Kim DK (2001) Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J Mol Cell Cardiol 33(2):295–305CrossRefGoogle Scholar
  2. Chaudhuri JB (1994) Refolding recombinant proteins: process strategies and novel approaches. Ann NY Acad Sci 721:374–385CrossRefGoogle Scholar
  3. Cohen AW, Carbajal JM, Schaeffer RC Jr (1999) VEGF stimulates tyrosine phosphorylation of beta-catenin and small-pore endothelial barrier dysfunction. Am J Physiol 277:2038–2049Google Scholar
  4. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126:886–894CrossRefGoogle Scholar
  5. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77(2):305–319CrossRefGoogle Scholar
  6. Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antib 10:127–142Google Scholar
  7. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46–88CrossRefGoogle Scholar
  8. Johnson ES, Blobel G (1999) Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J Cell Biol 147:981–994CrossRefGoogle Scholar
  9. Kuliopulos A, Walsh J (1994) Production, purification and cleavage of tandem repeats of tandem proteins. J Am Chem Soc 116:4599–4607CrossRefGoogle Scholar
  10. Lamsoul I, Lodewick J, Lebrun S, Brasseur R, Burny A, Gaynor RB, Bex F (2005) Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol Cell Biol 25:10391–10406CrossRefGoogle Scholar
  11. Lavallie ER, McCoy JM (1995) Gene fusion expression systems in Escherichia coli. Curr Opin Biotechnol 6:501–506CrossRefGoogle Scholar
  12. Li SJ, Hochstrasser M (1999) A new protease required for cell-cycle progression in yeast. Nature 398:246–251CrossRefGoogle Scholar
  13. Li SJ, Hochstrasser M (2003) The Ulp1 SUMO isopeptidase: distinct domains required for viability, nuclear envelope localization, and substrate specificity. J Cell Biol 160:1069–1081CrossRefGoogle Scholar
  14. Lin Z, Lei H (2008) Identification of a neutralizing scFv binding to human vascular endothelial growth factor 165 (VEGF165) using a phage display antibody library. Appl Biochem Biotechnol 144:15–26CrossRefGoogle Scholar
  15. Liew OW, Ching Chong JP, Yandle TG, Brennan SO (2005) Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites. Protein Expr Purif 41:332–340CrossRefGoogle Scholar
  16. Loll PJ (2003) Membrane protein structural biology: the high throughput challenge. J Struct Biol 142:144–153CrossRefGoogle Scholar
  17. Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR (2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics 5:75–86CrossRefGoogle Scholar
  18. Marblestone JG, Edavettal SC, Lim Y, Lim P, Zuo X, Butt TR (2006) Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci 15:182–189CrossRefGoogle Scholar
  19. Rando RF, Notkins AL (1994) Production of human monoclonal antibodies against rabies virus. Lyssaviruses. Springer, Berlin, pp 195–205Google Scholar
  20. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402–3408Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Biology, School of Chemistry and Life SciencesLishui UniversityZhejiangPeople’s Republic of China

Personalised recommendations